Abstract
Purpose: Radioactivity deposition in normal tissues limits the dose deliverable by radiopharmaceuticals (RP) in radioimmunotherapy (RIT). This study investigated the absorbed radiation dose in normal tissues for prostate cancer patients in comparison to breast cancer patients for 2 RPs using the monoclonal antibody (MAb) m170. Methods and Materials: 111In-DOTA-glycylglycylglycyl-l-p-isothiocyanatophenylalanine amide (GGGF)-m170 and 111In-1,4,7,10-tetraazacyclododecane-N,N′,N″,N″′-tetraacetic acid (DOTA) 2-iminothiolane (2IT)-m170, representing the same MAb and chelate with and without a cleavable linkage, were studied in 13 breast cancer and 26 prostate cancer patients. Dosimetry for 90Y was calculated using 111In MAb pharmacokinetics from the initial imaging study for each patient, using reference man- and patient-specific masses. Results: The reference man-specific radiation doses (cGy/MBq) were not significantly different for the breast and the prostate cancer patients for both RPs in all but one tissue-RP combination (liver, DOTA-2IT). The patient-specific doses had differences between the groups most of which can be related to weight differences. Conclusions: Similar normal tissue doses were calculated for two groups of patients having different cancers and genders. This similarity combined with continued careful analysis of the imaging data might allow the use of higher starting doses in early phase RIT studies.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 1192-1198 |
| Number of pages | 7 |
| Journal | International Journal of Radiation Oncology Biology Physics |
| Volume | 66 |
| Issue number | 4 |
| DOIs | |
| State | Published - Nov 15 2006 |
Fingerprint
Keywords
- DOTA-peptide
- Monoclonal antibody
- Normal tissue dose
- Radiation dose
- Radioimmunotherapy
ASJC Scopus subject areas
- Oncology
- Radiology Nuclear Medicine and imaging
- Radiation
Cite this
Comparison of normal tissue pharmacokinetics with 111In/90Y monoclonal antibody m170 for breast and prostate cancer. / Lehmann, Joerg; Denardo, Gerald L; Yuan, Aina; Shen, Sui; O'Donnell, Robert T; Richman, Carol M; DeNardo, Sally J.
In: International Journal of Radiation Oncology Biology Physics, Vol. 66, No. 4, 15.11.2006, p. 1192-1198.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Comparison of normal tissue pharmacokinetics with 111In/90Y monoclonal antibody m170 for breast and prostate cancer
AU - Lehmann, Joerg
AU - Denardo, Gerald L
AU - Yuan, Aina
AU - Shen, Sui
AU - O'Donnell, Robert T
AU - Richman, Carol M
AU - DeNardo, Sally J.
PY - 2006/11/15
Y1 - 2006/11/15
N2 - Purpose: Radioactivity deposition in normal tissues limits the dose deliverable by radiopharmaceuticals (RP) in radioimmunotherapy (RIT). This study investigated the absorbed radiation dose in normal tissues for prostate cancer patients in comparison to breast cancer patients for 2 RPs using the monoclonal antibody (MAb) m170. Methods and Materials: 111In-DOTA-glycylglycylglycyl-l-p-isothiocyanatophenylalanine amide (GGGF)-m170 and 111In-1,4,7,10-tetraazacyclododecane-N,N′,N″,N″′-tetraacetic acid (DOTA) 2-iminothiolane (2IT)-m170, representing the same MAb and chelate with and without a cleavable linkage, were studied in 13 breast cancer and 26 prostate cancer patients. Dosimetry for 90Y was calculated using 111In MAb pharmacokinetics from the initial imaging study for each patient, using reference man- and patient-specific masses. Results: The reference man-specific radiation doses (cGy/MBq) were not significantly different for the breast and the prostate cancer patients for both RPs in all but one tissue-RP combination (liver, DOTA-2IT). The patient-specific doses had differences between the groups most of which can be related to weight differences. Conclusions: Similar normal tissue doses were calculated for two groups of patients having different cancers and genders. This similarity combined with continued careful analysis of the imaging data might allow the use of higher starting doses in early phase RIT studies.
AB - Purpose: Radioactivity deposition in normal tissues limits the dose deliverable by radiopharmaceuticals (RP) in radioimmunotherapy (RIT). This study investigated the absorbed radiation dose in normal tissues for prostate cancer patients in comparison to breast cancer patients for 2 RPs using the monoclonal antibody (MAb) m170. Methods and Materials: 111In-DOTA-glycylglycylglycyl-l-p-isothiocyanatophenylalanine amide (GGGF)-m170 and 111In-1,4,7,10-tetraazacyclododecane-N,N′,N″,N″′-tetraacetic acid (DOTA) 2-iminothiolane (2IT)-m170, representing the same MAb and chelate with and without a cleavable linkage, were studied in 13 breast cancer and 26 prostate cancer patients. Dosimetry for 90Y was calculated using 111In MAb pharmacokinetics from the initial imaging study for each patient, using reference man- and patient-specific masses. Results: The reference man-specific radiation doses (cGy/MBq) were not significantly different for the breast and the prostate cancer patients for both RPs in all but one tissue-RP combination (liver, DOTA-2IT). The patient-specific doses had differences between the groups most of which can be related to weight differences. Conclusions: Similar normal tissue doses were calculated for two groups of patients having different cancers and genders. This similarity combined with continued careful analysis of the imaging data might allow the use of higher starting doses in early phase RIT studies.
KW - DOTA-peptide
KW - Monoclonal antibody
KW - Normal tissue dose
KW - Radiation dose
KW - Radioimmunotherapy
UR - http://www.scopus.com/inward/record.url?scp=33750343587&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33750343587&partnerID=8YFLogxK
U2 - 10.1016/j.ijrobp.2006.06.020
DO - 10.1016/j.ijrobp.2006.06.020
M3 - Article
C2 - 16965873
AN - SCOPUS:33750343587
VL - 66
SP - 1192
EP - 1198
JO - International Journal of Radiation Oncology Biology Physics
JF - International Journal of Radiation Oncology Biology Physics
SN - 0360-3016
IS - 4
ER -